German pharmaceutical company Schott Pharma is set to make its debut on the Frankfurt Stock Exchange, having set its initial public offering (IPO) price at €27 ($28.36). The pricing, announced on Thursday, falls within the projected range of €24.50 and €28.50.
The valuation puts Schott Pharma's market capitalization at around €4.1 billion. The firm anticipates gross proceeds of €935 million from the sale of 34.6 million shares. The parent company, Schott, plans to retain a significant majority stake of at least 77% following the IPO.
In a noteworthy development, Qatar Holding has secured a 4.9% stake in Schott Pharma through an investment of €200 million. The IPO and subsequent listing on the Frankfurt Stock Exchange represent a significant milestone for Schott Pharma in its growth trajectory. It will be closely watched by investors and industry stakeholders alike as it unfolds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.